Tysabri and PML in Georgia: What Clinicians Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a patient on Tysabri has developed new neurological symptoms such as confusion, vision changes, or weakness, understanding the link to progressive multifocal leukoencephalopathy (PML) is critical. Building on decades of research into immunosuppressive therapies, this page outlines key clinical questions for Georgia healthcare providers and patients facing a PML diagnosis.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri specifically due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically leads to death or severe disability, and the warning emphasizes that healthcare professionals must monitor patients for any new signs or symptoms suggestive of the condition. The clinical presentation of PML can vary but often includes progressive neurological deficits such as weakness, vision changes, speech difficulties, and cognitive decline. Diagnosis is confirmed through brain imaging and detection of JC virus DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is central to the drug's efficacy in multiple sclerosis but also creates the vulnerability that leads to PML.

Risk Factors and FDA Warnings

Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The FDA-approved labeling instructs that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML. Despite these warnings, cases continue to occur, raising questions about the adequacy of risk communication and monitoring in clinical practice. The TOUCH Prescribing Program was established to ensure that patients are informed of the risks and that only certified providers prescribe and administer Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, even with these measures, patients may not fully appreciate the severity of the PML risk or the importance of early reporting of symptoms.

Statute of Limitations for Tysabri Claims in Georgia

For patients in Georgia who have developed PML after Tysabri exposure, legal considerations regarding the statute of limitations are critical. In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between exposure and documented harm can be variable. The infection may develop months to years after starting Tysabri, and early symptoms can be subtle, mimicking multiple sclerosis relapses. This delay in diagnosis can affect when the statute of limitations begins to run. Patients and their families should be aware that the clock may start ticking from the date of diagnosis or from when symptoms first became apparent, depending on the circumstances. The adequacy of warnings regarding Tysabri and PML is a central issue in potential legal claims. While the boxed warning is prominent, some argue that the risk was not sufficiently communicated to patients and prescribers early in the drug's history.

Legal Recourse and Next Steps

Attorney-related considerations for affected patients include the need to preserve medical records, document the timeline of Tysabri use and symptom onset, and consult with legal counsel experienced in pharmaceutical litigation. Expert medical testimony may be required to establish causation and the link between Tysabri and the development of PML. In summary, Tysabri-associated PML is a serious and often devastating condition with a clear mechanistic basis and identifiable risk factors. Patients in Georgia who have been harmed must be mindful of the statute of limitations, which typically runs two years from discovery of the injury. The adequacy of warnings and the implementation of risk mitigation programs are key factors in evaluating potential legal claims. Anyone affected should seek prompt legal advice to protect their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Georgia?

In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries like Tysabri-associated PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. Because PML symptoms can be subtle and mimic other conditions, the clock may start from the date of diagnosis or when symptoms first became apparent. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable time frame.

What are the primary risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be carefully considered by healthcare providers when initiating and continuing Tysabri therapy.

How is PML diagnosed in patients taking Tysabri?

PML diagnosis is confirmed through brain imaging (typically MRI) and detection of JC virus DNA in cerebrospinal fluid. Clinical presentation often includes progressive neurological deficits such as weakness, vision changes, speech difficulties, and cognitive decline. Early diagnosis is critical, and Tysabri should be withheld immediately at the first sign or symptom suggestive of PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.